← Back to Search

Dopamine Agonist

Quinagolide 360 µg for Endometriosis (RAQUEL Trial)

Phase 2
Waitlist Available
Research Sponsored by Ferring Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline and at menstrual cycle 4 (around 4 months)
Awards & highlights

Summary

This trial is testing a vaginal ring that releases a medication called quinagolide to help reduce pain in women with moderate to severe endometriosis. The goal is to see if this treatment is effective.

Eligible Conditions
  • Endometriosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline and at menstrual cycle 4 (around 4 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline and at menstrual cycle 4 (around 4 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Changes in Bone Turnover Markers, Determined by Bone Formation Marker Serum Procollagen Type I N Propeptide (s-PINP)
Changes in Bone Turnover Markers, Determined by Bone Resorption Marker Serum C-terminal Crosslinking Telopeptide of Type 1 Collagen (s-CTx)
Changes in Circulating Levels of Clinical Chemistry Parameters: Alanine Aminotransferase
+75 more

Side effects data

From 2022 Phase 2 trial • 22 Patients • NCT03692403
33%
Corona virus infection
33%
Foot fracture
33%
Major depression
33%
Uterine disorder
100%
80%
60%
40%
20%
0%
Study treatment Arm
Quinagolide 720 µg - Part B
Quinagolide 1080 µg - Part B
Quinagolide 360 µg - Part A
Placebo - Part A
Quinagolide 720 µg - Part A
Quinagolide 360 µg - Part B
Quinagolide 1080 µg - Part A

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Quinagolide 720 µgExperimental Treatment1 Intervention
Vaginal ring containing Quinagolide 720 μg, with daily target release rate of 9 μg
Group II: Quinagolide 360 µgExperimental Treatment1 Intervention
Vaginal ring containing Quinagolide 360 μg, with daily target release rate of 4.5 μg
Group III: Quinagolide 1080 µgExperimental Treatment1 Intervention
Vaginal ring containing Quinagolide 1080 μg, with daily target release rate of 13.5 μg
Group IV: PlaceboPlacebo Group1 Intervention
Vaginal ring containing matching placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Quinagolide 360 µg
2018
Completed Phase 2
~30
Quinagolide 720 µg
2018
Completed Phase 2
~30
Quinagolide 1080 µg
2019
Completed Phase 2
~90

Find a Location

Who is running the clinical trial?

Ferring PharmaceuticalsLead Sponsor
321 Previous Clinical Trials
1,243,857 Total Patients Enrolled
2 Trials studying Endometriosis
97 Patients Enrolled for Endometriosis
Global Clinical ComplianceStudy DirectorFerring Pharmaceuticals
69 Previous Clinical Trials
1,160,174 Total Patients Enrolled
1 Trials studying Endometriosis
67 Patients Enrolled for Endometriosis
~3 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top